Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study

Journal of Viral Hepatitis

Volumn 18, Issue 6, 2011, Pages 393-399

  Puoti, C ^a   Barbarini, G ^b   Picardi, A ^c   Romano, M ^d   Pellicelli, A ^e   Barlattani, A ^f   Mecenate, F ^f   Guarisco, R ^a   Costanza, O M ^a   Spilabotti, L ^a   Bellis, L ^a,g   Bonaventura, M E ^h   Dell'Unto, O ^a   Elmo, M G ⁱ   Nicolini, A M ^a   Nosotti, L ^j   Soccorsi, F ^e  

^a Marino Hospital Rome   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c Liver Unit   (Italy)

^d SANDRO PERTINI HOSPITAL   (Italy)

^e SAN CAMILLO HOSPITAL   (Italy)

^f San Giacomo Hospital   (Italy)

^g Villa Betania Hospital   (Italy)

^h Rieti Hospital   (Italy)

ⁱ Local Health Centre RM A   (Italy)

^j SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

more..

Author keywords

HCV; normal ALT; peginterferon; rapid virological response; ribavirin; sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; ASTHENIA; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG FEVER; DRUG WITHDRAWAL; ERADICATION THERAPY; FATIGUE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IRRITABILITY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RAPID VIROLOGICAL RESPONSE; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955418333     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2010.01319.x     Document Type: Article

References (30)

1. Puoti C,. HCV carriers with persistently normal aminotransferase levels: normal does not always mean healthy. J Hepatol 2003; 38: 529-532. (Pubitemid 36399260)
2. Zeuzem S, Alberti A, Rosenberg W, et al. Management of patients with chronic hepatitis C virus infection and 'normal' aminotransferase activity. Aliment Pharmacol Ther 2006; 24: 1133-1149. (Pubitemid 44427502)
3. Puoti C, Magrini A, Stati T, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393-1398. (Pubitemid 27520001)
4. Marcellin P, Levy S, Erlinger S,. Therapy of Hepatitis C: patients with normal aminotransferase levels. National Institutes of Health Consensus Development Conference Panel Statement: management of hepatitis C. Hepatology 1997; 26 (Suppl.1): 133S-136S.
5. Tassopoulos NC,. Treatment in patients with normal ALT levels. EASL international consensus conference on hepatitis c: consensus statement. J Hepatol 1999; 30: 956-961.
6. Puoti C, Castellacci R, Montagnese F, et al. Histological and virological features and follow up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers [ISACC]. J Hepatol 2002; 37: 117-123. (Pubitemid 34713063)
7. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36: 973-977.
8. Puoti C, Guido M, Mangia A, Persico M, Prati D,. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35: 362-369. (Pubitemid 41110865)
9. Bacon BR,. Treatment of patients with hepatitis c and normal serum aminotransferase levels. Proceedings of the NIH consensus conference management of hepatitis C. Hepatology 2002; 36 (Suppl. 1): S179-S184. (Pubitemid 35253479)
10. Strader DB, Wright T, Thomas DL, Seef LB,. Diagnosis, management and treatment of hepatitis C. AASLD Practice Guideline. Hepatology 2004; 39: 1147-1171.
11. Dienstag JL, McHutchison JG,. American Gastroenterological Association [AGA] Medical Position Statement on the Management of Hepatitis C. Gastroenterology 2006; 130: 225-264.
12. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a [40KD] and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 1724-1732. (Pubitemid 39575851)
13. Snoeck E, Hadziyannis SJ, Puoti C, et al. Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alfa-2a (40KD) plus ribavirin. Liver Int 2008; 28: 61-71.
14. Puoti C, Pellicelli AM, Romano M, et al. Treatment of HCV carriers with persistently normal alanine aminotransferase levels with peginterferon alfa-2a and ribavirin: a multicentric study. Liver Int 2009; 29: 1479-1484.
15. Mangia A, Andriulli A,. Tailoring the length of antiviral treatment for hepatitis C. Gut 2010; 59: 1-5.
16. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-999. (Pubitemid 38670134)
17. Shiffman M, Suter F, Bacon BR, et al. for the ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3. N Engl J Med 2007; 357: 124-134. (Pubitemid 47057730)
18. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103. (Pubitemid 41772522)
19. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of chronic hepatitis C. J Viral Hepat 2009; 16: 75-90.
20. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
21. Ghany MG, Strader DB, Thomas DL, Seef LB,. Diagnosis, management and treatment of hepatitis C. Hepatology 2009; 49: 1335-1374.
22. Puoti C, Castellacci R, Montagnese F,. Hepatitis C virus carriers with normal aminotransferase levels: healthy people or true patients? Dig Liver Dis 2000; 32: 634-643.
23. Puoti C, Bellis L, Martellino F, et al. Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test. J Hepatol 2005; 43: 534-535. (Pubitemid 41111437)
24. Puoti C, Bellis L, Galossi A, et al. Antiviral Treatment of HCV carriers with normal ALT. Mini Rev Med Chem 2008; 8: 150-152. (Pubitemid 351320938)
25. Alberti A,. Towards a more individualised management of HCV patients with initially or persistently normal alanine aminotransferase levels. J Hepatol 2005; 42: 266-274. (Pubitemid 40143475)
26. Kronenberger B, Herrmann E, Micol F, von Wagner M, Zeuzem S,. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels. Hepatology 2004; 40: 1442-1449. (Pubitemid 39657020)
27. Deltenre P, Canva V, El Nady M, et al. A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study. J Viral Hepat 2009; 16: 500-505.
28. Moreno C, Deltenre P, Pawlotsky JP, Henrion J, Adler M, Mathurin P,. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. J Hepatol 2010; 52: 25-31.
29. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd) / ribavirin therapy. Hepatology 2006; 43: 954-960. (Pubitemid 43724620)
30. Puoti C, Bellis L, Guarisco R, Dell'Unto O, Spilabotti L, Mitidieri Costanza O,. HCV carriers with normal alanine aminotransferase levels: healthy persons or severely ill patients? Dealing with an everyday clinical problem. Eur J Intern Med 2010; 21: 57-61.